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 In patients with PBC at high-risk of disease progression,
budesonide in addition to UDCA did not improve liver
histology.
 Addition of budesonide was associated with improved bio-
chemical markers of PBC disease activity.
 Future trials of new therapies in PBC will benefit from the
use of a variety of clinical endpoints.
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Around one-third of patients with primary
biliary cholangitis (PBC) needs additional
medical therapy alongside ursodeoxycholic
acid (UDCA) treatment. In this clinical trial,
the addition of the corticosteroid budesonide
did not improve liver histology; there were
however relevant improvements in liver
blood tests.
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Saint-Antoine, Paris, FranceBackground & Aims: In patients with primary biliary cholangitis Serious adverse events occurred in 10 patients receiving bude-
(PBC), the efficacy of budesonide, a synthetic corticosteroid
displaying high first-pass metabolism, is unresolved. In a
placebo-controlled, double-blind trial, we evaluated the added-
value of budesonide in those with PBC and ongoing risk of pro-
gressive disease despite ursodeoxycholic acid (UDCA) treatment.
Methods: We evaluated 62 patients with PBC who had histo-
logically confirmed hepatic inflammatory activity, according to
the Ishak score, and an alkaline phosphatase (ALP) >1.5× upper
limit of normal (ULN), after at least 6 months of UDCA therapy.
Participants were randomly assigned 2:1 to receive budesonide
(9 mg/day) or placebo once daily, for 36 months, with UDCA
treatment (12–16 mg/kg body weight/day) maintained. Primary
efficacy was defined as improvement of liver histology with
respect to inflammation and no progression of fibrosis. Second-
ary outcomes included changes in biochemical markers of liver
injury.
Results: Recruitment challenges resulted in a study that was
underpowered for the primary efficacy analysis. Comparing pa-
tients with paired biopsies only (n = 43), the primary histologic
endpoint was not met (p >0.05). The proportion of patients with
ALP <1.67×ULN, a >−15% decrease in ALP and normal bilirubin was
higher in the budesonide group than in the placebo group at 12,
24, and 36 months (p <0.05, each). In contrast to placebo,
budesonide reduced mean ALP and 35% of budesonide-treated
patients achieved normalisation of ALP (placebo 9%; p = 0.023).words: Autoimmune liver disease; Treatment non-responder; Corticosteroids;
ical trial.
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Conclusion: Budesonide add-on therapy was not associated with
improved liver histology in patients with PBC and insufficient
response to UDCA; however, improvements in biochemical
markers of disease activity were demonstrated in secondary
analyses.
Lay summary: Around one-third of patients with primary biliary
cholangitis (PBC) needs additional medical therapy alongside
ursodeoxycholic acid (UDCA) treatment. In this clinical trial, the
addition of the corticosteroid budesonide did not improve liver
histology; there were however relevant improvements in liver
blood tests.
ClinicalTrials.gov number: NCT00746486.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Primary biliary cholangitis (PBC) is a chronic and usually pro-
gressive cholestatic liver disease with autoimmune features.1
End-stage biliary cirrhosis arises when patients have chronic
cholestatic hepatitis driven by a lymphocytic and destructive
cholangitis, as well as persistent interface hepatitis.2 Although an
autoimmune disease with regards to its underpinning risk fac-
tors, attempts at immunosuppressive treatment with agents
such as predniso(lo)ne, azathioprine, methotrexate, or cyclo-
sporine have largely failed due to a lack of efficacy and/or
concern over long-term side effects.3,4 Standard therapy in PBC
remains with ursodeoxycholic acid (UDCA) and second line
treatment with obeticholic acid (licenced) and fibric acid de-
rivatives (off-label); these therapies derive benefit by modu-
lating bile acid signalling at the level of hepatic and bile duct
epithelial cells and thereby, improve bile secretory capacity.5–7 In
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Fig. 1. Trial design. Patients were screened for eligibility and eligible patients
were randomly assigned 2:1 to receive either 9 mg/d budesonide or placebo on
top of 12–16 mg/kg bodyweight/day of UDCA. 6 mg/d budesonide was allowed
if aspartate aminotransferase (AST) values were normalized, i.e. dose adjust-
ment according to disease activity. After randomization, control visits were
performed at week 0, 2, and every 3 months. A follow-up visit was performed
4 weeks after end of study. AST, aspartate aminotransferase; BD, twice daily;
EOT, end of treatment; OD, once daily; TD, three times daily; UDCA, urso-
deoxycholic acid. *Dose adjustment down to 3 mg Budesonide BD allowed if
AST normal.
Research Article DILI, Autoimmune, Cholestatic and Genetic Diseasesto control disease as indicated by worsening of serum liver tests
such as alkaline phosphatase (ALP), aspartate aminotransferase
(AST), bilirubin or albumin is associated with progressive liver
fibrosis and development of cirrhosis.8,9 Current clinical trial
design for new therapies in PBC is thus based on biochemical
surrogate markers of disease activity which are reasonably likely
to predict patient outcome.
Patients with PBC frequently have histopathologic evidence of
an interface hepatitis, the features of which can be indistin-
guishable from corticosteroid responsive autoimmune hepatitis;
furthermore, the histologic appearances can be accompanied by
other features of autoimmune hepatocellular injury such as
increased serum aminotransferase activity as well as co-existent
autoantibodies.10 Budesonide is a potent synthetic corticosteroid
displaying high first-pass metabolism within the liver, resulting
in fewer systemic side effects compared to predniso(lo)ne. In
patients with PBC exhibiting ‘florid’ interface hepatitis on biopsy,
the efficacy of budesonide in improving liver histology and
biochemistry when used in combination with UDCA has been
reported in 2 studies conducted in non-cirrhotic, early stage
patients.11,12 Administration to patients with more advanced
disease provided only minimal benefits but enhanced the risk of
osteoporosis13; additionally budesonide is avoided in cirrhosis
because of the risk of portal vein thrombosis and uncontrolled
systemic shunting of the drug.14 The intent of therapy in part
reflects the association between serum aminotransferase activity
and interface hepatitis, and the association with disease pro-
gression in PBC. Equally relevant are in vitro data showing that
corticosteroids and UDCA are synergistic in increasing expres-
sion of the biliary chloride/bicarbonate anion exchanger 2
(AE2)15 and, thereby, biliary secretion of bicarbonate. This pro-
cess may stabilise the biliary bicarbonate umbrella, a protective
mechanism of biliary epithelia against uncontrolled invasion of
toxic bile acids.16
Herein, we report the final results of a 3-year phase-III dou-
ble-blind randomised placebo-controlled trial evaluating UDCA +
budesonide vs. UDCA + placebo. The aim of the present study was
to evaluate the impact of budesonide in patients incompletely
responding to standard UDCA treatment.
Patients and methods
Study design
This was a randomized, double-blind, placebo-controlled, mul-
ticentre, comparative phase III clinical study in patients with
non-cirrhotic PBC (Fig. 1); EudraCT number 2007-004040-70;
trial protocol available on request from Dr Falk Pharma GmBH.
The study took place from January 2009 until July 2015 in 23
study sites across 13 countries, with 6 active sites in Germany, 3
active sites in Denmark and 2 active sites in Austria. The study of
patients with PBC was conducted with 2 treatment arms in the
form of a parallel group comparison and served to compare the
efficacy, tolerability and safety of a combination therapy of UDCA
plus budesonide, against UDCA plus placebo.
The target population was non-cirrhotic patients with PBC
already treated with UDCA, who were at risk of disease pro-
gression based on >−1 of the following criteria: a) serum ALP >−3
×ULN at any time since diagnosis of PBC and alanine amino-
transferase (ALT) >−2×ULN; b) total bilirubin >−1 mg/dl; c) mod-
erate to severe periportal or periseptal lymphocytic interface
hepatitis or; d) periportal and portal fibrosis with numerous
septa (Ludwig stage III) without cirrhosis. A delay in patient322 Journal of Hepatology 2recruitment due to these strict criteria led to a protocol modifi-
cation 33 months after launching the study to allow for addi-
tional inclusion of patients with incomplete response to UDCA as
defined by the failure to achieve serum ALP values <1.5×ULN
after at least 6 months of treatment with UDCA and with in-
flammatory activity according to the modified hepatic activity
index (mHAI) sum score17 in the histological assessment of the
liver. Histological assessment had to be conducted no more than
6 months before baseline. In total, 48/62 (77%) treated patients
fulfilled the original inclusion criterion, 34/40 (85%) in the
budesonide group and 14/22 (64%) in the placebo group.
Patients were randomized centrally with an allocation ratio of
2:1 to 9 mg/d budesonide (1 × 3 mg capsule 3× daily) or placebo
(1 × capsule 3× daily). All patients concomitantly received 12–16
mg UDCA acid/kg bodyweight/day. The individual dose of
budesonide/placebo could be reduced depending on the AST
values (i.e. dose adjustment according to disease activity). If AST
values normalised at any time from the start of trial treatment, 2
capsules of budesonide/placebo were allowed (1 capsule in the
morning and 1 capsule in the evening). Randomisation was
performed using randomly permuted blocks and patients were
allocated to the next available randomisation number according
to the centrally prepared randomisation list. Participance for an
individual patient consisted of a 36-month treatment period
with 11 scheduled trial visits (V1–V11).
After the interim analysis in September 2017, the Independent
Data Monitoring Committee recommended terminating the
study, treating the remaining patients until they had completed
at least 1 year of treatment and then performing a termination
visit. The study was conducted in accordance with good clinical
practice, the Declaration of Helsinki, all applicable national laws,
and was approved by independent local ethics committees. Dr.
Falk Pharma GmbH were the study sponsor; all authors had
access to the results.Population
This study included female and male patients aged >−18 years
with a biopsy-proven diagnosis of PBC, who were anti-
mitochondrial antibody (AMA) positive on immunofluores-
cence >1:40, had received UDCA treatment for at least 6 months021 vol. 74 j 321–329
prior to baseline and had an incomplete response to UDCA
treatment.
Patients with histologically proven cirrhosis, HIV infection
and other clinically dominant chronic liver diseases including
hepatitis B or C infection, primary sclerosing cholangitis, Wil-
son’s disease, a1-anti-trypsin-deficiency, haemochromatosis and
auto-immune hepatitis (AIH) were excluded. Patients with PBC
and features of AIH treated insufficiently with UDCA mono-
therapy, could be enrolled. In addition, patients with densitom-
etry proven osteoporosis, hypertension (persistently raised blood
pressure >140/90 mmHg), diabetes mellitus and cataract(s) were
excluded. Further exclusion criteria can be found in the
supplementary material.
Procedures
Efficacy and safety assessments were conducted at baseline, at
the 9 interim visits (week 2, 4 and every 3 months thereafter),
and at end of treatment (EOT) at month 36 or withdrawal visit.
The baseline examinations were performed within 4 weeks. At
all visits vital signs were controlled and routine laboratory pa-
rameters were assessed including routine serum biochemistry
(ALT, AST, gamma-glutamyltransferase, ALP, total bilirubin, al-
bumin, total protein, serum creatinine, cholinesterase, glutamate
dehydrogenase), haematology (blood count and differential
blood count), and blood coagulation tests (international nor-
malised ratio [INR], partial thromboplastin time).
A liver biopsy was performed, according to standard medical
procedures, at baseline, if no liver biopsy had previously been
performed or if the last biopsy dated back more than 6 months. A
second liver biopsy was performed at the EOT/withdrawal visit.
Biopsies were analysed by 2 central pathologists (U. Drebber, D.
Wendum). The samples were processed according to standard
pathological methods. The severity of fibrosis/cirrhosis was
staged according to Ludwig.18 Inflammatory activity was rated
according to Desmet et al.19 and Ishak et al.17 Additional histo-
logical parameters were classified according to Pares et al.20
Further procedures are described in the supplementary material.
Study endpoints
Study design was based on regulatory feedback and discussion.
The primary efficacy variable was the response rate defined as
rate of patients with improvement of liver histology with respect
to inflammation (>−3 points in the mHAI sum score or no in-
flammatory activity according to Ishak et al.17) and no progres-
sion of fibrosis (staging according to Ludwig18) at the individual
last patient visit within the study compared to baseline.
A number of clinically meaningful secondary efficacy vari-
ables were evaluated. This included the rate of patients pre-
senting with cirrhosis or oesophageal varices and/or ascites at
the end of treatment; the rate of patients registered on the liver
transplant waiting list; or patients with liver-related death dur-
ing up to 3 years of treatment; the rate of patients with
improvement of liver histology with respect to stage (according
to Ludwig18); the rate of patients with improvement of liver
histology with respect to grade (according to Desmet et al.19) and
stage (according to Ludwig18); the rate of patients with
improvement of liver histology with respect to grade (according
to Desmet et al.19). Secondary efficacy variables included nor-
malisation of serum levels of ALP, or reduction of baseline ALP
levels by at least 40%; absolute (and % change in) ALP, bilirubin,
ALT and AST; rate of patients with ALP <−1.67×ULN AND >−15%Journal of Hepatology 2decrease in ALP AND total bilirubin within the normal limits at
12 months (last observation carried forward [LOCF]), 24 months
(LOCF), 36 months (LOCF); course of pruritus (measured by vi-
sual analogue scale [VAS]), course of fatigue and quality of life
(measured by PBC-40), course of the adapted Mayo Risk Score21
and the modified globe score, assessment of inflammatory ac-
tivity (mHAI score17), quality of life by PBC-40 and global
assessment of efficacy by patient and investigator.
Sample size and statistical analysis
The primary objective of the study was to demonstrate the su-
periority of a combination therapy with UDCA plus budesonide
compared to UDCA plus placebo in terms of the primary efficacy
variable. The primary efficacy variable was subjected to a
confirmatory statistical analysis (a = 0.025, one-sided). Analysis
was based on the methodology of Cochran-Mantel-Haenzel-Test
method with “patients at risk of disease progression” as a
stratification factor. Evaluations of secondary efficacy and safety
variables were performed for exploratory purposes.
After the pre-defined interim analysis, the sponsor decided to
stop the study due to insufficient recruitment but followed the
independent data monitoring committee recommendation to
treat patients already recruited for at least 1 year. Early termi-




A total of 90 patients were enrolled with all individuals providing
informed consent prior to study participation; 62 patients (69%)
fulfilled inclusion and exclusion criteria and were randomised.
All received at least 1 dose of study medication, and, were thus
evaluated in the safety and intention-to-treat (ITT) population.
Forty patients (65%) were allocated to the 9 mg/d budesonide
group, while 22 patients (36%) received placebo in addition to
UDCA (Fig. 2).
Among 62 patients treated with study medication, 33 (53%)
patients withdrew from the trial prematurely (budesonide: 23/
40 patients [58%]; placebo: 10/22 patients [46%]). The only dif-
ferences between the treatment groups regarding the percent-
ages of patients withdrawn from the study concerned AEs
(budesonide: 8/40 patients [20%]; placebo: 0/22 patients [0%]). A
total of 42 patients were excluded from the ITT population to
form the per protocol (PP) analysis set (n = 20). The most
frequent reasons for exclusion from the ITT analysis set were
premature termination (25/62 patients [40%]), efficacy data after
baseline not available (19/62 patients [31%]), and adherence (17/
62 patients [27%]). Three patients in the budesonide group and 1
patient in the placebo group stopped the study at 1 year. Of
these, 1 patient in the budesonide group and the placebo patient
had a final biopsy.
The percentages of patients excluded from the PP analysis set,
by reason for exclusion, were similar in both treatment groups.
Table 1 shows baseline demographics; no clinically relevant
differences were present between treatment groups, neither for
the ITT nor the PP population. There were minor imbalances in
the proportion of patients at risk of disease progression and the
intensity of pruritus was higher in the placebo group. Histolog-
ical evaluation showed a qualitative difference for less fibrosis,
portal inflammation and lower mHAI score in the placebo group







3 mg Budesonide TD +
12-16 mg/kg BW UDCA OD
n = 40
Placebo +
12-16 mg/kg BW UDCA OD
n = 22
Enrolled, randomized and treated
n = 62
Safety and ITT population 
Excluded due to 
major protocol violations 
n = 28
Reasons for exclusion*:
- Premature discontinuation: n = 18
- Compliance: n = 14
- No efficacy data after baseline: n = 14
- Treatment duration <12 months: n = 10
- Concomitant medication: n = 7
- Incl./excl. criteria not met: n = 3
Excluded due to 
major protocol violations 
n = 14
Reasons for exclusion*:
- Premature discontinuation: n = 7
- Compliance: n = 3
- No efficacy data after baseline: n = 5
- Treatment duration <12 months: n = 4
- Concomitant medication: n = 6
- Incl./excl. criteria not met: n = 3
- EOT/withdrawal visit >75 days 
  after last study drug administration: n = 1
Excluded due to violation
of inclusion/exclusion criteria
n = 28 
Major reasons for exclusion*:
- Patients at no risk of disease 
  progression: n = 5
- Osteoporosis: n = 6
- Hypertension: n = 5
- Cirrhosis: n = 3
Fig. 2. Patient characteristics. Flow diagram of the progress through the phases of the parallel randomised trial (enrolment, intervention allocation, follow-up,
and data analysis). EOT, end of treatment; ITT, intention to treat; OD, once daily; PP, per-protocol; TD, three times daily; UDCA, ursodeoxycholic acid. *Multiple
reasons for exclusion were applicable for some patients.
Research Article DILI, Autoimmune, Cholestatic and Genetic Diseasespatients completed 3 years of treatment (17 patients in the
budesonide group and 12 patients in the placebo group). All
patients included during the first 33 months before the modifi-
cation of the trial population showed incomplete response to
UDCA as defined by ALP <1.5×ULN.
Primary efficacy
In the ITT analysis of the primary endpoint, 11/40 (28%) patients
in the budesonide and 5/22 (23%) patients in the placebo group
showed a response at 36 months (LOCF). Thus, the observed
difference (4%; p = 0.36) could not confirm superiority of bude-
sonide compared to placebo regarding the primary endpoint. The
results of the subgroup analyses by country, by duration of study
participation and by being at risk of disease progression did not
support any differences between the treatment groups within
each subgroup.
With regard to the primary efficacy variable among the 43
patients with paired biopsies (baseline and EOT), the response
rate in the budesonide group (11/26 patients [42%]) was
numerically higher than in the placebo group (5/17 (29%);
Fig. 3A). Further histological evaluations were inconclusive
(Fig. 3B). However, portal inflammation improved more in the
budesonide group (mean [SD] change in mHAI score −1.3 [2.1])
than the placebo group (−0.3 [3.6]).324 Journal of Hepatology 2Secondary efficacy analyses
In the ITT population (budesonide n = 40, placebo n = 22) starting
from Month 12 (LOCF), the proportion of patients with ALP <−1.67
×ULN and >−15% decrease in ALP AND total bilirubin in the normal
limits was higher in the budesonide group than the placebo
group (p = 0.029; 12 months, and p = 0.021; 24 months) (Fig. 4A).
At Month 36 (LOCF), these criteria were met in 17/40 patients
(43%) in the budesonide group and 5/22 patients (23%) in the
placebo group (p = 0.038). ALP improved in the budesonide
group compared to the placebo group (p <0.05; Fig. 4B and
Table 3) and a reduction of at least 40% in ALP values was
observed in 19/40 (48%) and 4/22 (18%) patients in the budeso-
nide and placebo group, respectively. Consistently, normalisation
of ALP occurred more often after budesonide treatment (35%)
than after placebo treatment (9%; p = 0.023; Fig. 4C and Table 3).
Serum bilirubin increased in the placebo group (0.6 mg/dl), but
not in the budesonide group (−0.02 mg/dl; Fig. 4D and Table 3).
Serum ALT and AST improved in the budesonide group compared
to the placebo group (p <0.05 each; Fig. 4E,F and Table 3).
The adapted Mayo Risk Score did not change in the budeso-
nide group (LOCF, mean change from baseline [SD] 0.006 [0.3]),
but slightly increased in the placebo group (0.2 [0.8]). Changes in
modified GLOBE score were small, showing a small reduction in
the budesonide group (LOCF, mean change from baseline [SD] 0.3
[0.5]) and essentially no change in the placebo group (0.06 [0.8]).021 vol. 74 j 321–329






Female, n (%) 38 (95) 22 (100)
Age, years 54 [10] 51 [12]
BMI, kg/m2 24.2 [8.8] 25.7 [5.0]
Duration of disease, year 7.4 [9.6] 5.0 [10.8]
Patients at risk of disease progression* 34 (85) 14 (64)
Alkaline phosphatase, U/L 262 [286] 256 [210]
Alkaline phosphatase >1.67×ULN 30 (75) 17 (77)
Total bilirubin, mg/dl 0.55 [0.63] 0.61 [0.23]
Total bilirubin >ULN at baseline 9 (23) 1 (5)
ALT, U/L 70 [56] 76 [62]
AST, U/L 44 [37] 54 [33]
GGT, U/L 183 [307] 197 [351]
Albumin, U/L 4.4 [0.3] 4.2 [0.5]
Prothrombin time, INR 0.9 [0.1] 0.9 [0.1]
Pruritus VAS, cm 1.2 [4.0] 2.2 [7.0]
Categorical variables are presented as n (%) and continuous variables are presented as
median [IQR].
ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index;
GGT, gamma-glutamyltransferase; INR, international normalised ratio; PBC, primary
biliary cholangitis; ULN, upper limit of normal; VAS, visual analogue scale.
*Risk of disease progression was defined by fulfilling one or more of the following
criteria: serum alkaline phosphatase >−3× the upper limit of normal (corresponding to
312 U/L for women and 387 U/L for men) at any time since diagnosis of PBC OR ALT or
AST >−2× upper limit of normal (corresponding to 70 U/L for women and 100 U/L for
men) at inclusion OR moderate to severe periportal or periseptal lymphocytic
interface hepatitis OR periportal and portal fibrosis with numerous septa (Ludwig
stage III) without cirrhosis.






Fibrosis (Ludwig score), n (%)*
Stage 1 1 (3) 3 (14)
Stage 2 17 (43) 12 (55)
Stage 3 22 (55) 7 (32)
Inflammatory activity (Desmet score)*
Grade 1 2 (5) 4 (18)
Grade 2 30 (75) 15 (68)
Grade 3 8 (20) 3 (13)
Periportal or periseptal interface
hepatitis (piecemeal necrosis), n (%)*
Absent 1 (3) 1 (5)
Mild (focal, few portal areas) 15 (38) 10 (46)
Mild/moderate (focal, most portal areas) 12 (30) 6 (27)
Moderate (continuous around
<50% of tracts or septa)
10 (25) 4 (18)
Severe (continuous >50% of tracts or septa) 2 (5) 1 (5)
Confluent necrosis, n (%)
Absent 29 (73) 17 (77)
Focal confluent necrosis 11 (28) 5 (23)
Portal inflammation, n (%)*
Mild, some or all portal areas 3 (8) 4 (18)
Moderate, some or all portal areas 15 (38) 10 (46)
Moderate/marked, all portal areas 16 (40) 8 (36)
Marked, all portal areas 6 (15) 0 (0)
mHAI sum score*, median (IQR) 7 (3) 6 (2)
mHAI, modified hepatic activity index.
*Derived by using the ‘consent’ value. In case of mHAI scores equally assessed by the
2 pathologists the values of the first central pathologist were used for the single
items of mHAI score at baseline.During up to 3 years of treatment, the rate of clinical events
(cirrhosis or oesophageal varices and/or ascites at EOT, or pa-
tients registered on the liver transplant waiting list, or patients
with liver-related death) was low and did not differ between the
budesonide group (1/40 [3%]) and the placebo group (2/22 [9%];
p = 0.93, Cochran-Mantel-Haenzel-Test with “patients at risk of
disease progression” as a stratification factor).
Symptoms
Pruritus as measured by VAS remained unchanged in the
budesonide group (LOCF, mean change from baseline [SD]: −0.3
[2.3]) compared to a slight increase in the placebo group (0.6
[3.1]). Quality of Life remained unchanged (Table 3).
Safety
In total, 60/62 patients (97%) experienced AEs (Table 4; 98% and
96% in the budesonide group and placebo group, respectively).
Arthralgia, osteopenia, cataract(s), muscle spasms, hypertension,
dyspepsia, weight increase, abdominal pain, peripheral oedema
and blood cortisol decrease were noticeably more frequent in the
budesonide group than in the placebo group, some of these are
commonly observed effects after long-term therapy with glu-
cocorticoids. On the other hand, pruritus, diarrhoea and nausea
were more common in the placebo group (Table 4).
No deaths were reported. Serious adverse events (SAEs;
defined as per international practice) were reported in 25/40
patients (63%) in the budesonide group and in 14/22 patients
(64%) in the placebo group. Most of the SAEs were related to the
planned investigational liver biopsy (22/40 patients [55%] in the
budesonide group and 11/22 patients [50%] in the placebo group).
Next to SAEs of liver biopsy, 17 SAEs occurred in 12 patients
during the study and were distributed across diverse preferredJournal of Hepatology 2terms without relevant differences between the 2 treatment
groups: 8/40 patients (20%) with 10 SAEs in the budesonide group
and 6/22 patients (27%) with 7 SAEs in the placebo group.
Frequencies of AEs leading to discontinuation of study drug
were higher under budesonide than under placebo treatment,
i.e. 9/40 patients (23%) in the budesonide group and 2/22 pa-
tients (9%) in the placebo group. Adverse drug reactions were
reported in 24/40 patients (60%) in the budesonide group and in
8/22 patients (36%) in the placebo group. The proportion of
drug-related AEs (budesonide/placebo) was higher in the
budesonide group, especially regarding the preferred terms
blood cortisol decrease (6 patients [15%]), cataract (5 patients
[13%]), hypertension (5 patients [13%]) and osteopenia (4 pa-
tients [10%]), for which no cases were reported in the placebo
group.
In the budesonide group, 8/40 (20%) patients reduced their
budesonide dose at various time points; in the placebo group, 2/
22 (9%) patients reduced their daily medication. Of the drop-
outs, 3/23 (13%) in the budesonide group reduced their dose
before the premature termination. In 2 cases, the drop-out was
after 28 months budesonide therapy and the dose reduction was
close to the study termination in only 1 case (3 months). In
contrast, 5/8 (63%), of the patients with dose reduction
completed the study.
Laboratory assessments showed slight suppression of adrenal
function and effects on bone metabolism in the budesonide
group (Table S1). Serum cortisol was slightly reduced in the
budesonide group compared to baseline and placebo. Further-
more, there was a slight reduction in bone-specific ALP, N-MID
Osteocalcin and the T-Scores of femoral neck and lumbar spine in






































































Fig. 3. Histological efficacy variables. (A) Improvement of liver histology with
respect to inflammation (an improvement by at least 3 points in the Ishak sum
score or no inflammatory activity) and no progression of fibrosis (Ludwig
staging), compared to baseline at the individual last patient visit within the
study, paired biopsies only. (B) Improvement of liver histology with respect to
stage (Ludwig) and grade (Desmet). *Cochran-Mantel-Hentzel Test stratified
according to stratification factor “patients at risk of disease progression”.
Research Article DILI, Autoimmune, Cholestatic and Genetic DiseasesDiscussion
Herein, we report on a prospective, randomised, placebo-
controlled trial assessing the addition of oral budesonide for pa-
tients with PBC and an incomplete response to UDCA alone. We
describe the therapeutic impact of budesonide, as measured by
change over time in histology and serum liver tests. We found no
additional improvement in predefined histologic outcomes
compared to placebo, even though the mHAI-score decreased
more from baseline (−1.3 [2.1]) in the budesonide group than in
the placebo group (−0.3 [3.7]). However, improvements in rele-
vant biochemical surrogates of disease activity were found.
Therapy was well tolerated but systemic effects of long-term
corticosteroid use were evident. We also demonstrate the sig-
nificant real-world challenges of completing an adequately
powered clinical trial in PBC if serial liver biopsies are mandatory.
Although there are 2 licenced therapies for PBC,5 as well as
off-label data on fibric acid derivatives,7 there remains an unmet
need for treatment options that address the clinically evident
spectrum of inflammatory liver disease. Budesonide is a non-
halogenated corticosteroid with potent dual agonism for the
glucocorticoid and xenobiotic pregnane X receptor, which ex-
hibits a high (90%) first-pass effect through the liver when
administered orally, thus mitigating systemic bioavailability and
related side effects.14,22 Prior clinical studies have suggested a
benefit when budesonide is added to treatment approaches in
PBC.11,12
Significant challenges in trial recruitment, possibly related to
the regulatory need for paired liver biopsies, finally resulted in
the termination of this study prior to the recruitment of suffi-
cient patient numbers. However, we now report the findings of
this double-blind, placebo-controlled, but underpowered trial in
patients with non-cirrhotic PBC and an incomplete biochemical
response to UDCA (ALP >1.5×ULN) as well as a liver biopsy
showing inflammatory activity. In our study, patients were
randomly assigned 2:1 to oral budesonide 9 mg/day or placebo,
alongside UDCA (12–16 mg/kg/d), for 36 months. The primary
endpoint agreed with regulators during the design of the trial –
an improvement of >−3 points in the mHAI sum score or no in-
flammatory activity according to Ishak and no progression of326 Journal of Hepatology 2fibrosis stage – did not differ between groups. However, the
proportion of patients with serum ALP values <1.67×ULN and a
>−15% drop in ALP from baseline and normal bilirubin – more
recently acknowledged by regulatory authorities in Europe and
North America as a valid surrogate criterion reflecting favourable
long-term prognosis in PBC – was significantly higher in the
budesonide group than in the placebo group at 12, 24, and 36
months. Budesonide was associated with significantly reduced
serum cortisol concentration and lumbar spine bone density;
adverse event monitoring was also reported more frequently in
patients treated with budesonide.
Several notable themes arise when evaluating these data.
Firstly, the study was designed with a histologic endpoint. PBC is
a rare and heterogeneous inflammatory liver disease, wherein
features of disease are classic but not archetypal.2 In addition to
the challenges of consistent biopsy interpretation and the slow
nature of histologic changes in a disease, liver biopsy is invasive
and increasingly not used clinically in the diagnosis and man-
agement of PBC.5 Therefore, the trial design and the trial activ-
ities differed from clinical practice in the treatment of patients
with PBC. In this setting, recruitment of patients was ultimately a
factor in study deliverability, even accepting that liver histology
provides important information on safety and efficacy in the
development of new therapies for patients with liver disease.
Furthermore, data on histology are inconclusive for the following
limitations: first, only a much smaller number of patients than
initially planned in the sample size calculation had biopsies at
baseline and at 3 years. Thus, the study is underpowered for
histology. The secondary analyses were not formally powered;
such power calculations allow only a statement about whether
an actually existing effect may not be detected. In the analyses,
we report a statistically significant difference between budeso-
nide and placebo for the secondary endpoint. Thus, the degree of
confidence in the result itself is already covered by the level of
significance. Second, a subset of patients had biopsies at baseline
and at 1 year only due to early termination caused by the sub-
stantial recruitment problems. One year is most likely too short
to reflect potential treatment effects on histology. Furthermore, it
is notable that even for the standard therapy, UDCA, very well
powered and longer duration clinical trials were needed to meet
a histologic end-point.23 At the time of study design and biopsy
interpretation, more contemporary PBC histologic grading and
staging approaches (e.g. Nakanuma) were not in widespread use,
and as a result we were unable to evaluate treatment efficacy
with methods beyond those described. In addition, a recent trial
assessing the efficacy of bezafibrate as add-on therapy for pa-
tients with PBC could not detect changes in liver histology
despite a strong reduction of biochemical surrogate markers of
disease activity.7 Equally whilst non-invasive tests such as elas-
tography are not designed to replace careful histologic assess-
ment, they do provide valuable adjunctive data on liver stiffness
related to inflammation and fibrosis. However, at the time of
study conduct, elastography was not widely available. Overall,
this study points to the need to carefully consider the role of liver
biopsy in PBC trials.
Within PBC, there is also the ongoing challenge of correctly
defining overlap syndromes, particularly AIH. In the context of a
study such as this, ultimately some discretion rests with in-
vestigators and our approach was to focus on the patient history
in this regard: based on a review of case histories, there was 1

























































































































































































Fig. 4. Biochemical efficacy variables. (A) Proportion of patients with serum
levels of ALP <−1.67 ULN and >−15% decrease and normal total bilirubin at
different months after baseline (LOCF). (B) Serum levels of ALP at baseline and
LOCF. (C) Proportion of patients with normalized ALP at month 36 (LOCF).
(D) Serum levels of total bilirubin at baseline and LOCF. (E) Serum levels of ALT
at baseline and LOCF. (F) Serum levels of AST at baseline and LOCF. *Cochran-
Mantel-Hentzel Test stratified according to stratification factor “patients at risk
of disease progression”; **Fisher’s Exact Test; ALP, alkaline phosphatase; ALT,
alanine aminotransferase, AST, aspartate aminotransferase; LOCF, last obser-
vation carried forward.






Baseline 70 (56) 76 (50)
Change from baseline (LOCF) −12 (30) 0 (47)
AST [U/L]
Baseline 58 (39) 68 (62)
Change from baseline (LOCF) −13 (19) 4 (47)
ALP [U/L]
Baseline 327 (227) 367 (289)
Change from baseline (LOCF) −95 (166) −9 (177)
Normalization (LOCF), n (%) 14 (35) 2 (9)
>−40% reduction (LOCF), n (%) 19 (47) 4 (18)
Total bilirubin [mg/dl]
Baseline 0.75 (0.46) 0.67 (0.41)
Change from baseline (LOCF) −0.02 (0.44) 0.59 (2.22)
mHAI-Score
Baseline 6.9 (2.1) 6.1 (2.2)
Change from baseline (LOCF) −1.3 (2.1) -0.3 (3.7)
Pruritus VAS [cm]
Baseline 2.4 (2.9) 3.3 (3.4)
Change from baseline (LOCF) −0.3 (2.3) 0.6 (3.1)
PBC-40 - Quality of Life
Domain: Symptoms
Baseline 17.0 (5.2) 18. 5 (4.7)
Change from baseline (LOCF) 0.1 (3.0) 1.7 (2.8)
Domain: Itch
Baseline 5.7 (3.4) 6.5 (4.1)
Change from baseline (LOCF) −0.5 (2.8) 0.5 (1.2)
Domain: Fatigue
Baseline 26.8 (11.8) 32.8 (13.3)
Change from baseline (LOCF) −1.6 (7.1) −0.4 (9.3)
Domain: Cognition
Baseline 11.7 (5.4) 14.0 (4.8)
Change from baseline (LOCF) 0.4 (4.0) 0.4 (3.0)
Domain: Social
Baseline 18.4 (8.6) 19.7 (7.4)
Change from baseline (LOCF) −0.1 (5.4) 2.5 (8.6)
Domain: Emotional
Baseline 7.6 (3.4) 8.8 (3.7)
Change from baseline (LOCF) 0.1 (2.6) 0.2 (3.5)
Data presented as mean (SD).
ALP, serum alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; LOCF, last observation carried forward; mHAI, modified hepatic
activity index; VAS, visual analogue scale.budesonide group (2/40; 5%); in the placebo group, there was
only 1 patient with ‘AIH’ (1/22; 5%). A final limitation we
acknowledge but believe not to be material is a late biochemical
effect of UDCA therapy: 8/40 individuals (20%) in the treatment
group had <12 months between diagnosis and first use of study
medication; 5/22 (27%) individuals in the placebo arm had <12
months between diagnosis and first use of study medication.
Current clinical trial activity, in part because of many of the
issues we report herein, now has a focus on robust surrogates of
disease activity.24 In this respect, the secondary analyses provide
more consistent evidence that add-on budesonide may be
beneficial. However, this must be interpreted in the context of
secondary analyses, for which there were distinctions in patientJournal of Hepatology 2ascertainment and inclusion criteria compared to other recent
PBC clinical trials. Nevertheless, if compared to an end-point that
has been applied to a conditionally licenced therapy (obeticholic
acid),6 we report that the proportion of patients with ALP <−1.67
×ULN and a >−15% decrease in ALP AND normal total bilirubin was
significantly higher in the budesonide group than the placebo
group (Fig. 4A). Consistently, normalisation of ALP occurred more
often after budesonide treatment than after placebo treatment
and a >−40% reduction in ALP was also more often observed in the
budesonide group.6
Tolerability of budesonide was in line with prior experience,
and as expected there were treatment-related dropouts. Never-
theless, recommending budesonide use for a chronic disease
such as PBC remains a challenge if duration of therapy is
considered. The induction dose of budesonide used in the pre-
sent study was higher (9 mg/day) than in a previous study.12 In
that regard, whilst no new safety signals emerged from our
study, long-term clinical use of budesonide, even dose adjusted,
will need to accommodate the potential for harmful effects on
bone health for example.25 Further evaluation of the impact of021 vol. 74 j 321–329 327
Table 4. Overview of treatment-emergent AEs (safety population).
Budesonide (N = 40)
n (%)
Placebo (N = 22)
n (%)
AEs 39 (98) 21 (96)
TEAEs 39 (98) 21 (96)
Follow-up AEs 3 (8) 3 (14)
Serious TEAEs 25 (63) 14 (64)
AEs leading to premature
discontinuation of the study
medication
9 (23) 2 (9)
ADRsa 24 (60) 8 (36)
Most common AEsb
Headache 18 (45) 9 (41)
Nasopharyngitis 10 (25) 5 (23)
Pruritus 6 (15) 7 (32)
Back pain 7 (18) 4 (18)
Hypertension 8 (20) 2 (9)
Bronchitis 6 (15) 3 (14)
Influenza-like illness 6 (15) 3 (14)
Abdominal pain upper 5 (13) 4 (18)
Pain in extremity 5 (13) 3 (14)
Nausea 4 (10) 4 (18)
Cataract 6 (15) 2 (9)
Muscle spasms 6 (15) 1 (5)
Blood cortisol decreased 6 (15) 0 (0)
Arthralgia 6 (15) 0 (0)
Osteopenia 6 (15) 0 (0)
Diarrhoea 2 (5) 4 (18)
Osteoporosis 5 (13) 1 (5)
Oropharyngeal pain 4 (10) 2 (9)
Cough 3 (8) 3 (14)
Dyspepsia 5 (13) 1 (5)
Weight increased 5 (13) 0 (0)
Abdominal pain 5 (13) 0 (0)
Oedema peripheral 5 (13) 0 (0)
Fatigue 4 (10) 1 (5)
ADRs, adverse drug reactions; AE, adverse event; TEAE, treatment emergent adverse
event; PT, preferred term.
aTEAE or post-treatment AE with causal relationship assessed at least as possible to
Budesonide and/or Placebo. AEs due to the planned liver biopsies within the study
are not listed.
bOccurred in at least 5 patients of the safety population.
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